

## **Seattle Genova**

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

## Interferon-α2a In Vitro Transcribed mRNA-LNP

Catalog Number:SG-MRNA-LNP-1884

Gene Name       IFN-α2a         Source       The ORF of Interferon-α2a was cloned in our IVT vector and mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102).         Alternative names       Interferon-α2a         SPECIFICATIONS         Cap       m7GpppN         5'-UTR       5'-untranslated region derived from human alpha-globin RNA with a optimized Kozak sequence         ORF       Interferon-α2a         3'-UTR       3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12s ribosomal RNA         Poly(A) Tail       A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another radenosine residues.         Modifications       N1-methyl-pseudouridine         Neutral Lipid       1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)         Cholesterol       Cholesterol         Lonizable Lipid       1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)         PEG-lipid       Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxoctyl)amino)octanoate)(SM-102)         Storage       -20 °C         Buffer       PBS, pH7.4         Cryoprotectant       Trehalose	Product Name	Interferon-α2a In Vitro Transcribed mRNA-LNP
Source The ORF of Interferon-α2a was cloned in our IVT vector and mRNA w prepared through in vitro transcription and purification. The purified mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102).  Alternative names Interferon-α2a  SPECIFICATIONS  Cap m7GpppN  5'-untranslated region derived from human alpha-globin RNA with a optimized Kozak sequence  ORF Interferon-α2a  3'-UTR 3'-UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications N1-methyl-pseudouridine  Neutral Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol Cholesterol  Lonizable Lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession		
prepared through in vitro transcription and purification. The purified mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102).  Alternative names Interferon-α2a  SPECIFICATIONS  Cap m7GpppN  5'-UTR 5'-untranslated region derived from human alpha-globin RNA with a optimized Kozak sequence  ORF Interferon-α2a  3'-UTR 3'-UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications N1-methyl-pseudouridine  Neutral Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol Cholesterol  Lonizable Lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession	Gene Name	
SPECIFICATIONS  Cap m7GpppN  5'-UTR 5'-untranslated region derived from human alpha-globin RNA with a optimized Kozak sequence  ORF Interferon-α2a  3'-UTR 3'-UTR 3'-UTR omprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications N1-methyl-pseudouridine  Neutral Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol Cholesterol  Lonizable Lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose	Source	prepared through in vitro transcription and purification. The purified mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-
Cap       m7GpppN         5'-UTR       5'-untranslated region derived from human alpha-globin RNA with a optimized Kozak sequence         ORF       Interferon-α2a         3'-UTR       3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA         Poly(A) Tail       A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another radenosine residues.         Modifications       N1-methyl-pseudouridine         Neutral Lipid       1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)         Cholesterol       Cholesterol         Lonizable Lipid       1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)         PEG-lipid       Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)         Storage       -20 °C         Buffer       PBS, pH7.4         Cryoprotectant       Trehalose         BACKGROUND	Alternative names	Interferon-α2a
5'-untranslated region derived from human alpha-globin RNA with a optimized Kozak sequence  ORF Interferon-α2a  3'-UTR 3'-UTR 3'-UTR aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications N1-methyl-pseudouridine  Neutral Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol Cholesterol  Lonizable Lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession	SPECIFICATIONS	
optimized Kozak sequence  ORF Interferon-α2a  3'-UTR 3'-UTR omprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another radenosine residues.  Modifications N1-methyl-pseudouridine  Neutral Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol Cholesterol  Lonizable Lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession	Cap	m7GpppN
3'-UTR 3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications N1-methyl-pseudouridine  Neutral Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol Cholesterol  Lonizable Lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession	5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA  Poly(A) Tail  A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications  N1-methyl-pseudouridine  Neutral Lipid  1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol  Lonizable Lipid  1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid  Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)  Storage  -20 °C  Buffer  PBS, pH7.4  Cryoprotectant  Trehalose  BACKGROUND  Gene Accession	ORF	Interferon-α2a
residues, followed by a 10-nucleotide linker sequence and another adenosine residues.  Modifications  N1-methyl-pseudouridine  Neutral Lipid  1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol  Lonizable Lipid  1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid  Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)—8-oxooctyl)amino)octanoate)(SM-102)  Storage  -20 °C  Buffer  PBS, pH7.4  Cryoprotectant  Trehalose  BACKGROUND  Gene Accession	3'-UTR	aminoterminal enhancer of split (AES) mRNA and the mitochondrial
Neutral Lipid  1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)  Cholesterol  Lonizable Lipid  1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid  Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)—8-oxooctyl)amino)octanoate)(SM-102)  Storage  -20 °C  Buffer  PBS, pH7.4  Cryoprotectant  Trehalose  BACKGROUND  Gene Accession	Poly(A) Tail	A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues.
Cholesterol  Lonizable Lipid  1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid  Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)—8-oxooctyl)amino)octanoate)(SM-102)  Storage  -20 °C  Buffer  PBS, pH7.4  Cryoprotectant  Trehalose  BACKGROUND  Gene Accession	Modifications	N1-methyl-pseudouridine
Lonizable Lipid  1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)  PEG-lipid  Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)—8-oxooctyl)amino)octanoate)(SM-102)  Storage  -20 °C  Buffer  PBS, pH7.4  Cryoprotectant  Trehalose  BACKGROUND  Gene Accession	Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
(PEG2000-DMG)  PEG-lipid Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)—8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession	Cholesterol	Cholesterol
8-oxooctyl)amino)octanoate)(SM-102)  Storage -20 °C  Buffer PBS, pH7.4  Cryoprotectant Trehalose  BACKGROUND  Gene Accession	Lonizable Lipid	
Buffer PBS, pH7.4 Cryoprotectant Trehalose  BACKGROUND Gene Accession	PEG-lipid	
Cryoprotectant Trehalose  BACKGROUND  Gene Accession	Storage	-20 °C
BACKGROUND  Gene Accession	Buffer	PBS, pH7.4
Gene Accession	Cryoprotectant	Trehalose
	BACKGROUND	
Gene Alias Interferon-α2a	Gene Accession	
	Gene Alias	Interferon-α2a



## **Seattle Genova**

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

proliferation activities of IFN- $\alpha$  2a. IFN- $\alpha$  proteins are widely used as standard treatments during antiviral and antineoplastic therapies. The IFN- $\alpha$  2a variant differs from IFN- $\alpha$  2b by one amino acid.

## Background

Human IFN- $\alpha$ 2a is a recombinant protein optimized for use in cell culture, differentiation studies, and functional assays. Interferon- $\alpha$  2a (IFN- $\alpha$  2a) is a type I interferon made by leukocytes during viral infection. The JAK-STAT pathway mediates the antiviral and anti-cell